Corporate Profile

Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Over 100 issued patents support the Stereotaxis platform. Stereotaxis' core Epoch™ Solution includes the Niobe® ES remote magnetic navigation system, the Odyssey® portfolio of lab optimization, networking and patient information management systems, and the Vdrive™ robotic navigation system and consumables, which have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere.

Financial News

Stereotaxis technology included in recommendations to reduce fluoroscopy exposure and described as a

Revenue of $7.6 million for the fourth quarter and $31.2 million for the full year 2017 Fourth qu

First Procedures Performed at Toronto’s Sunnybrook Health Sciences Centre ST. LOUIS, Dec. 05, 2017

ExchangeOTCQX (US Dollar)
Change (%) Stock is Up 0.01 (1.32%)
Data as of 02/23/18 3:59 p.m. ET
Minimum 20 minute delay
Refresh quote

Powered By EDGAR Online

Recent Filings
Filing DateForm
Receive E-mail Alerts
Alerts are e-mailed to you whenever certain new company information is posted to this site.
Enter your e-mail address here:
Investor Presentation
Download Documentation Q4 Investor Presentation
Investor Contacts
Martin Stammer
Chief Financial Officer
Stereotaxis, Inc.

© Copyright Stereotaxis 2015